about the MicroVas system

a patented, FDA 510-K registered, non-invasive vascular treatment device that delivers electrical currents to targeted areas within the human body. MicroVas delivers a powerful, deeply penetrating waveform that causes blood to pump more efficiently through the micro circulation in damaged tissue (drain the venous beds and raise tissue oxygen levels) to accelerate the healing process. MicroVas’ therapeutic effects are dramatic and lasting.  Health care professionals familiar with MicroVas consider it an important new tool in the treatment of neuropathy, non-healing wounds, repetitive motion disorders, fibromyalgia, sports injuries and many other conditions related to vascular insufficiency.

history of MicroVas

Technology developed for U.S. Navy To treat SEALS for hypothermia 1988 -1989

FDA 510-K Registration 1990

MicroVas Technologies, Inc. (MTI) formed 02/01

Diabetic non-healing wounds validated by treating 1,000's of Native Americans in Oklahoma free for 2 years

Patent issued by US Patent Office to MTI 06/04

neuroVasix formed through patients and investors and obtained from MTI the EXCLUSIVE rights to Make and Market the MicroVas Technology and began worldwide marketing efforts (License Agreement) 03/05
neuroVasix invests and grows MicroVas product to approximately 1,000 systems wordwide

neuroVasix sues MTI for breach of licensing contract 12/07

     neuroVasix awarded PERMANENT INJUNCTION UPHOLDING EXCLUSIVE LICENSE 3/10


about neuroVasix

established in May 2005 as a privately owned company, neuroVasix obtained the EXCLUSIVE RIGHTS TO MAKE AND MARKET THE MicroVas TECHNOLOGY.  Since then, it has sold and supports about 1,000 systems in many markets, having sold systems to medical doctors, osteopathic physicians, podiatrists, physical therapists, various clinics, hospitals, veteran homes, nursing homes, professional athletes and sports teams. As neuroVasix expands its sales, each of these markets will continue to be of significant importance. Currently, neuroVasix management is focusing its sales efforts in three major areas:  treatment of neuropathy, treatment of wounds, and podiatry.

NOTE:  any systems sold by MTI are in direct violation of the permanent injunction issued by the COURT against them, which states:  "MTI is prohibited from making, having made, using, importing, offering for sale or selling the MicroVas Device or any other product that includes or practices the technology that is set forth in the patents used in the MicroVas Device."  As such,  neuroVasix  will exercise its judgement in regards to servicing any systems purchased other than through neuroVasix, which would not be warrantied by neuroVasix.